Atlanta Allergy & Asthma

Atlanta Allergy & Asthma operates as a healthcare provider specializing in allergy and asthma treatment services within the United States. The organization manages sensitive patient health information, including insurance documentation, medical claims, and clinical audit records, as part of its standard operations. Its exposure of protected health data during a cybersecurity incident indicates involvement in billing processes, insurance coordination, and detailed patient case management. The compromised records spanned multiple years, reflecting an extensive patient base and longitudinal care activities typical of established medical practices.

The organization gained attention following a March 2021 ransomware attack by the Nefilim threat group, which exfiltrated approximately 19GB of compressed files containing clinical and financial data. Attackers extracted insurance records, outstanding claims documentation, and multi-page patient audits, subsequently leaking 1.3GB of sample data on dark web platforms to pressure payment. This breach exposed vulnerabilities in the entity's data protection measures, particularly concerning electronically stored remittance details and billing documents. The threat actors publicly listed Atlanta Allergy & Asthma on their leak site, confirming the theft of records affecting thousands of individuals. The organization maintained no public response to inquiries about the incident's resolution or mitigation efforts, leaving its post-breach remediation strategies undocumented.

This incident underscores the operational risks facing specialized healthcare providers managing sensitive datasets. The scope of compromised information—encompassing clinical audits, insurance workflows, and financial records—highlights the organization's role in integrated healthcare delivery systems. While the attack did not publicly disclose corporate structure details, the targeting by sophisticated ransomware actors suggests the entity's perceived capacity to meet extortion demands. The absence of subsequent disclosures leaves unresolved questions about long-term impacts on patient privacy and institutional reputation within the medical sector.